BI 730357 PoCC and dose ranging in Psoriasis
Research payments
$2,806,542
Through program year 2022, $2,806,542 in research payments was reported against BI 730357 PoCC and dose ranging in Psoriasis, across 98 payments, paid by Boehringer Ingelheim Pharmaceuticals, Inc..
- Paid by
- Boehringer Ingelheim Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $101,416 | 12 |
| 2021 | Research | $435,051 | 18 |
| 2020 | Research | $728,593 | 32 |
| 2019 | Research | $1,541,481 | 36 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- James Krell Birmingham, AL Named on 8 payments
- Tiffani Hamilton Alpharetta, GA Named on 7 payments
- Stephen Tyring Webster, TX Named on 7 payments
- David Pariser Norfolk, VA Named on 6 payments
- Richard Beasley Rapid City, SD Named on 6 payments
- Howard Sofen Los Angeles, CA Named on 5 payments
- Patricia Lee Webster, TX Named on 5 payments
- Martin Menter Dallas, TX Named on 5 payments
- Todd Schlesinger Charleston, SC Named on 4 payments
- Jerry Bagel East Windsor, NJ Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.